Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.52 |
| ▸ | AR | P10275 | 3/20 | 0.52 |
| ▸ | CNR1 | P21554 | 6/20 | 0.47 |
| ▸ | CNR2 | P34972 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2614950 | 0.86 | ESR1 (0.70) | ESR1ESR2ARTDP1 | |
| SCHEMBL29492899 | 0.86 | ESR1 (0.70) | ESR1ESR2ARTDP1 | |
| SCHEMBL56223 | 0.83 | ALDH1A1 (0.61) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL340143 | 0.83 | NPC1 (0.55) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL9154408 | 0.83 | RAB9A (0.48) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL13096081 | 0.82 | SHBG (0.57) | ESR1ESR2ARCNR1CNR2 | |
| Butane SCHEMBL6673989 | 0.80 | ALDH1A1 (0.57) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL1900996 | 0.80 | SMN1; SMN2 (0.44) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL674323 | 0.79 | ALDH1A1 (0.67) | ESR1ESR2ARLMNAMAPK1 | |
| SCHEMBL13204224 | 0.79 | ESR1 (0.71) | ESR1ESR2ARCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024147288-A1 | PATTERN FORMING METHOD, PATTERN FORMING KIT, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | 富士フイルム株式会社 | 2024-07-11 | — | — | WO | disclosed |
| US-10800732-B2 | Substituted malonamides and their use as antibacterial drugs | NATIONAL TAIWAN UNIVERSITY (TW) | 2020-10-13 | — | — | US | disclosed |
| US-8232039-B2 | Polymer and resist composition comprising the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8173352-B2 | Resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100151380-A1 | RESIST COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100136481-A1 | RESIST COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100124719-A1 | Polymer and Resist Composition Comprising the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-05-20 | — | — | US | disclosed |
| US-20100113678-A1 | FLUORINE-CONTAINING NOVOLAC RESIN, FLUORINE-CONTAINING SURFACTANT, FLUORINE-CONTAINING SURFACTANT COMPOSITION, AND RESIN COMPOSITION | DIC CORPORATION (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100081085-A1 | Polymer and Resist Composition Comprising the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | ESR1 273/4885ESR2 191/4885AR 86/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | ESR1 3695/4885ESR2 2631/4885AR 254/4885 |
| US-10800732-B2 | Substituted malonamides and their use as antibacterial drugs | NAAA, MAL2, MGAM | ESR1 1889/4885ESR2 2503/4885AR 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.